<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162433</url>
  </required_header>
  <id_info>
    <org_study_id>14-019H</org_study_id>
    <nct_id>NCT02162433</nct_id>
  </id_info>
  <brief_title>The Effect of Dexmedetomidine on Airway Complications After Deep or Awake Extubation</brief_title>
  <official_title>Does Dexmedetomidine Decrease the Incidence of Untoward Airway Events After Deep or Awake Extubation in Patients Undergoing Adenotonsillectomy With or Without Myringotomy and Tube Placement?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to investigate the effect of dexmedetomidine on the perioperative
      respiratory complications in this patient population undergoing both awake and deep tracheal
      extubation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose a prospective double-blinded randomized controlled trial. 336 pediatric patients
      presenting to Massachusetts Eye and Ear Infirmary (MEEI) for adenotonsillectomy who are
      eligible for the study based on inclusion and exclusion criteria will be recruited. A
      Clinical Pharmacy specialist, will be in charge of preparing the dexmedetomidine and placebo
      doses and will randomize the patients to four equally numbered groups. The anesthesiologist
      will receive the assignment for the extubation method in a sealed envelope from the Clinical
      Pharmacy specialist. Multiple parameters will be recorded in perioperative period to quantify
      perioperative adverse respiratory events.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to a high number of protocol deviations secondary to non-study approved opioid
    administration.
  </why_stopped>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">April 23, 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Respiratory Complications</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of patients exhibiting any of the following outcomes:
desaturation to less than 95% for more than 10 seconds;
breath holding;
complete or partial laryngospasm;
bronchospasm;
croup;
number of episodes of persistent cough (three or more consecutive coughs);
negative pressure pulmonary edema;
stridor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Emergence Agitation</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of patients with an incidence of emergence agitation post-surgery defined by the Pediatric Anesthesia Emergence Delirium (PAED) scale of &gt;10.
Emergence agitation is characterized by non-purposeful movement, restlessness, thrashing, incoherence, inconsolability, and unresponsiveness. The PAED is a scale used to assess emergence agitation in our patient population. It's minimum value is zero and maximum value is 20, with 0 being no emergence agitation and 20 being the most agitated state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Postoperative Nausea and Vomiting (PONV)</measure>
    <time_frame>24 hrs</time_frame>
    <description>Number of patients who experienced postoperative nausea and vomiting (PONV) as noted by the parental questionnaire administered 24 hours after the patient is discharged.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Time From End of Surgery to Leaving the Operating Room</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Average Time From Admission to the PACU to Discharge Home (Excluding Overnight Admission)</measure>
    <time_frame>24 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Needing Follow-up Pain Medication</measure>
    <time_frame>24 hours</time_frame>
    <description>24-hour postoperative pain medication requirement assessed by a parental questionnaire administered 24 hours after discharge. The parents are asked whether their child took any pain medication within the last 24 hours since the surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Unplanned Hospital Admission</measure>
    <time_frame>24 hours</time_frame>
    <description>Any unplanned hospital admission due to perioperative respiratory adverse events.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Adenotonsillar Hypertrophy</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Tonsillitis</condition>
  <condition>Adenoiditis</condition>
  <arm_group>
    <arm_group_label>1. Awake extubation/dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Awake extubation receiving dexmedetomidine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Awake extubation/placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Awake extubation receiving placebo (normal saline).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.Deep extubation/dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Deep extubation receiving dexmedetomidine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4. Deep extubation/placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Deep extubation receiving placebo (normal saline).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>to arms 2,4. Serves as the placebo.</description>
    <arm_group_label>2. Awake extubation/placebo</arm_group_label>
    <arm_group_label>4. Deep extubation/placebo</arm_group_label>
    <other_name>0.9% Sodium Chloride Solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>to arms 1,3</description>
    <arm_group_label>1. Awake extubation/dexmedetomidine</arm_group_label>
    <arm_group_label>3.Deep extubation/dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 3 to 16 years of age undergoing adenotonsillectomy, with or without
             myringotomy or myringoplasty

          -  ASA 1 &amp; 2

        Exclusion Criteria:

          -  Known allergy or hypersensitivity reaction to dexmedetomidine

          -  Organ dysfunction (renal/hepatic failure or leukemia)

          -  Cardiac disease (congenital or acquired)

          -  Airway or thoracic malformation

          -  Cerebral palsy

          -  Hypotonia

          -  Need for premedication

          -  Current/recent upper respiratory infection (within four weeks prior to the surgery)

          -  Asthma

          -  Allergy or intolerance to clonidine

          -  Non-English speaking parents/patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Makara Cayer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MEEI/ Harvard Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MEEI</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2014</study_first_posted>
  <results_first_submitted>February 12, 2020</results_first_submitted>
  <results_first_submitted_qc>April 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 9, 2020</results_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>Makara Cayer</investigator_full_name>
    <investigator_title>Prinicpal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tonsillitis</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT02162433/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT02162433/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT02162433/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1. Awake Extubation/Dexmedetomidine</title>
          <description>Awake extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
        </group>
        <group group_id="P2">
          <title>2. Awake Extubation/Placebo</title>
          <description>Awake extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
        </group>
        <group group_id="P3">
          <title>3.Deep Extubation/Dexmedetomidine</title>
          <description>Deep extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
        </group>
        <group group_id="P4">
          <title>4. Deep Extubation/Placebo</title>
          <description>Deep extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1. Awake Extubation/Dexmedetomidine</title>
          <description>Awake extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
        </group>
        <group group_id="B2">
          <title>2. Awake Extubation/Placebo</title>
          <description>Awake extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
        </group>
        <group group_id="B3">
          <title>3.Deep Extubation/Dexmedetomidine</title>
          <description>Deep extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
        </group>
        <group group_id="B4">
          <title>4. Deep Extubation/Placebo</title>
          <description>Deep extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="23"/>
            <count group_id="B5" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="23"/>
                    <count group_id="B5" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="23"/>
                    <count group_id="B5" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.64" spread="3.21"/>
                    <measurement group_id="B2" value="6.1" spread="2.89"/>
                    <measurement group_id="B3" value="6.52" spread="2.79"/>
                    <measurement group_id="B4" value="6.64" spread="2.8"/>
                    <measurement group_id="B5" value="6.48" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="23"/>
                    <count group_id="B5" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="23"/>
                    <count group_id="B5" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Respiratory Complications</title>
        <description>Number of patients exhibiting any of the following outcomes:
desaturation to less than 95% for more than 10 seconds;
breath holding;
complete or partial laryngospasm;
bronchospasm;
croup;
number of episodes of persistent cough (three or more consecutive coughs);
negative pressure pulmonary edema;
stridor.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1. Awake Extubation/Dexmedetomidine</title>
            <description>Awake extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
          </group>
          <group group_id="O2">
            <title>2. Awake Extubation/Placebo</title>
            <description>Awake extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
          </group>
          <group group_id="O3">
            <title>3.Deep Extubation/Dexmedetomidine</title>
            <description>Deep extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
          </group>
          <group group_id="O4">
            <title>4. Deep Extubation/Placebo</title>
            <description>Deep extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Respiratory Complications</title>
          <description>Number of patients exhibiting any of the following outcomes:
desaturation to less than 95% for more than 10 seconds;
breath holding;
complete or partial laryngospasm;
bronchospasm;
croup;
number of episodes of persistent cough (three or more consecutive coughs);
negative pressure pulmonary edema;
stridor.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Emergence Agitation</title>
        <description>Number of patients with an incidence of emergence agitation post-surgery defined by the Pediatric Anesthesia Emergence Delirium (PAED) scale of &gt;10.
Emergence agitation is characterized by non-purposeful movement, restlessness, thrashing, incoherence, inconsolability, and unresponsiveness. The PAED is a scale used to assess emergence agitation in our patient population. It's minimum value is zero and maximum value is 20, with 0 being no emergence agitation and 20 being the most agitated state.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1. Awake Extubation/Dexmedetomidine</title>
            <description>Awake extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
          </group>
          <group group_id="O2">
            <title>2. Awake Extubation/Placebo</title>
            <description>Awake extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
          </group>
          <group group_id="O3">
            <title>3.Deep Extubation/Dexmedetomidine</title>
            <description>Deep extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
          </group>
          <group group_id="O4">
            <title>4. Deep Extubation/Placebo</title>
            <description>Deep extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Emergence Agitation</title>
          <description>Number of patients with an incidence of emergence agitation post-surgery defined by the Pediatric Anesthesia Emergence Delirium (PAED) scale of &gt;10.
Emergence agitation is characterized by non-purposeful movement, restlessness, thrashing, incoherence, inconsolability, and unresponsiveness. The PAED is a scale used to assess emergence agitation in our patient population. It's minimum value is zero and maximum value is 20, with 0 being no emergence agitation and 20 being the most agitated state.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Postoperative Nausea and Vomiting (PONV)</title>
        <description>Number of patients who experienced postoperative nausea and vomiting (PONV) as noted by the parental questionnaire administered 24 hours after the patient is discharged.</description>
        <time_frame>24 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1. Awake Extubation/Dexmedetomidine</title>
            <description>Awake extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
          </group>
          <group group_id="O2">
            <title>2. Awake Extubation/Placebo</title>
            <description>Awake extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
          </group>
          <group group_id="O3">
            <title>3.Deep Extubation/Dexmedetomidine</title>
            <description>Deep extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
          </group>
          <group group_id="O4">
            <title>4. Deep Extubation/Placebo</title>
            <description>Deep extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postoperative Nausea and Vomiting (PONV)</title>
          <description>Number of patients who experienced postoperative nausea and vomiting (PONV) as noted by the parental questionnaire administered 24 hours after the patient is discharged.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Time From End of Surgery to Leaving the Operating Room</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1. Awake Extubation/Dexmedetomidine</title>
            <description>Awake extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
          </group>
          <group group_id="O2">
            <title>2. Awake Extubation/Placebo</title>
            <description>Awake extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
          </group>
          <group group_id="O3">
            <title>3.Deep Extubation/Dexmedetomidine</title>
            <description>Deep extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
          </group>
          <group group_id="O4">
            <title>4. Deep Extubation/Placebo</title>
            <description>Deep extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Time From End of Surgery to Leaving the Operating Room</title>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.15" spread="5.5"/>
                    <measurement group_id="O2" value="18.05" spread="7.43"/>
                    <measurement group_id="O3" value="10.29" spread="3.73"/>
                    <measurement group_id="O4" value="11.77" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Average Time From Admission to the PACU to Discharge Home (Excluding Overnight Admission)</title>
        <time_frame>24 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1. Awake Extubation/Dexmedetomidine</title>
            <description>Awake extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
          </group>
          <group group_id="O2">
            <title>2. Awake Extubation/Placebo</title>
            <description>Awake extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
          </group>
          <group group_id="O3">
            <title>3.Deep Extubation/Dexmedetomidine</title>
            <description>Deep extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
          </group>
          <group group_id="O4">
            <title>4. Deep Extubation/Placebo</title>
            <description>Deep extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Average Time From Admission to the PACU to Discharge Home (Excluding Overnight Admission)</title>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="345.06" spread="91.23"/>
                    <measurement group_id="O2" value="320.19" spread="69.07"/>
                    <measurement group_id="O3" value="341.53" spread="73.85"/>
                    <measurement group_id="O4" value="328.05" spread="93.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Needing Follow-up Pain Medication</title>
        <description>24-hour postoperative pain medication requirement assessed by a parental questionnaire administered 24 hours after discharge. The parents are asked whether their child took any pain medication within the last 24 hours since the surgery.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1. Awake Extubation/Dexmedetomidine</title>
            <description>Awake extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
          </group>
          <group group_id="O2">
            <title>2. Awake Extubation/Placebo</title>
            <description>Awake extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
          </group>
          <group group_id="O3">
            <title>3.Deep Extubation/Dexmedetomidine</title>
            <description>Deep extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
          </group>
          <group group_id="O4">
            <title>4. Deep Extubation/Placebo</title>
            <description>Deep extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Needing Follow-up Pain Medication</title>
          <description>24-hour postoperative pain medication requirement assessed by a parental questionnaire administered 24 hours after discharge. The parents are asked whether their child took any pain medication within the last 24 hours since the surgery.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Unplanned Hospital Admission</title>
        <description>Any unplanned hospital admission due to perioperative respiratory adverse events.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1. Awake Extubation/Dexmedetomidine</title>
            <description>Awake extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
          </group>
          <group group_id="O2">
            <title>2. Awake Extubation/Placebo</title>
            <description>Awake extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
          </group>
          <group group_id="O3">
            <title>3.Deep Extubation/Dexmedetomidine</title>
            <description>Deep extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
          </group>
          <group group_id="O4">
            <title>4. Deep Extubation/Placebo</title>
            <description>Deep extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Unplanned Hospital Admission</title>
          <description>Any unplanned hospital admission due to perioperative respiratory adverse events.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours post-op</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1. Awake Extubation/Dexmedetomidine</title>
          <description>Awake extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
        </group>
        <group group_id="E2">
          <title>2. Awake Extubation/Placebo</title>
          <description>Awake extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
        </group>
        <group group_id="E3">
          <title>3.Deep Extubation/Dexmedetomidine</title>
          <description>Deep extubation receiving dexmedetomidine.
Dexmedetomidine: to arms 1,3</description>
        </group>
        <group group_id="E4">
          <title>4. Deep Extubation/Placebo</title>
          <description>Deep extubation receiving placebo (normal saline).
Normal Saline: to arms 2,4. Serves as the placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Post-extubation low SaO2</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>PACU low SaO2</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Tonsil Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Post-extubation persistent cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>PACU persistent cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Laryngospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Post-Extubation Stridor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>PACU stridor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Post-Extubation Croup</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>PACU Croup</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Post-Extubation Breath Holding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>PACU Breath Holding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Makara Cayer</name_or_title>
      <organization>Massachusetts Eye and Ear</organization>
      <phone>617-573-3380</phone>
      <email>makara_cayer@meei.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

